Archer Materials has pinpointed a capillary blood collection method that matches venous samples in haemolysis levels, advancing its potassium Biosensor development towards integrated clinical testing.
- Early-stage study with 20 donors completed
- Capillary blood collection method shows low haemolysis
- Findings inform beta prototype engineering and workflow
- Supports design of future pilot and pivotal studies
- Data to underpin planned FDA regulatory engagement
Capillary Collection Method Matches Venous Blood
Archer Materials (ASX:AXE) has taken a crucial step in its potassium Biosensor development by completing an early pre-pilot blood collection study involving 20 donors. The study compared conventional venous blood draws with several capillary (finger-prick) collection techniques, revealing a capillary method that produces haemolysis levels broadly comparable to venous samples. This is significant because haemolysis; damage to red blood cells during collection; can artificially elevate potassium readings, complicating accurate measurement.
Engineering Inputs for Beta Prototype and Workflow
Beyond the sensor’s raw performance, Archer is focusing on the entire sample-to-result process, recognising that how blood is collected and processed can introduce errors. The study’s insights will shape the engineering of Archer’s beta prototype and its blood sample workflow, ensuring haemolysis is minimised and accurately accounted for. This integrated approach builds on previous work developing a haemolysis sensor, moving from detection towards managing sample quality in real-world conditions.
Pathway to Clinical and Regulatory Milestones
While the study is not a clinical validation, its findings are critical for designing future pilot and pivotal studies. Archer plans to combine the preferred capillary collection method with its blood processing and Biosensor technologies to evaluate the complete system. These data will also support regulatory strategy, including a planned Pre-Submission to the US Food and Drug Administration (FDA), a key step towards market approval.
CEO Emphasises Integrated Development Focus
CEO Dr Simon Ruffell highlighted the importance of understanding pre-analytical factors affecting potassium measurement: "Damage to red blood cells during collection can release potassium into the sample and potentially lead to an artificially high result. This study gives us valuable information about how different collection approaches affect the quality of the blood sample and how we should engineer our overall testing workflow."
Positioning Amid Broader Quantum and Biochip Progress
This announcement complements Archer’s recent strides in quantum chip manufacturing and biochip beta prototype development, backed by a $7 million capital raise earlier in 2026. The potassium Biosensor project is a key pillar in Archer’s medical diagnostics push, leveraging its semiconductor and quantum technology expertise. The integration of sample collection and haemolysis management reflects a mature engineering approach as the company edges closer to clinical evaluation phases.
Bottom Line?
Archer’s identification of a low-haemolysis capillary collection method marks a pivotal engineering milestone, setting the stage for integrated system testing and regulatory engagement.
Questions in the middle?
- How will Archer’s integrated beta prototype perform in upcoming pilot studies?
- What regulatory hurdles remain after the planned FDA Pre-Submission?
- Could the capillary collection method scale effectively for commercial deployment?